Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246738 · ClinicalTrials.gov registry record
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 87
- Enrollment target
NCT02246738: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02246738 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246738 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 87 participants
- Enrollment target
Study Summary
Purposes are to determine whether various cohorts of bladder cancer patients have detectable tCTC's, determine it tCTC levels vary with the natural history of bladder cancer and to see if tCTC's provide novel information.Study population are various cohorts of patients diangosed with urothelial carcinoma of the bladder.Procedures include a venous blood draw, up to two times, over a 6 month period for collection of tCTC's. Up to 15 mL's of blood will be collected at each blood draw.
Interventions
- OTHER Blood Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2014-08 |
| Est. Completion | 2020-10 |
What the finished NCT02246738 record still lists
NCT02246738 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 87 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Collection is the first listed.
NCT02246738 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02246738 about?
NCT02246738 is a clinical study titled "Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts". Purposes are to determine whether various cohorts of bladder cancer patients have detectable tCTC's, determine it tCTC levels vary with the natural history of bladder cancer and to see if tCTC's provide novel information.Study population are various cohorts of patients diangosed with urothelial carc...
What is the current status of trial NCT02246738?
This trial is currently completed. The enrollment target is 87 participants. The study started on 2014-08. Estimated completion is 2020-10.
What interventions are being tested in trial NCT02246738?
The interventions under investigation include: Blood Collection (OTHER).
Who is sponsoring clinical trial NCT02246738?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia